Longeveron Inc. Common Stock (LGVN)
Longeveron Inc. (LGVN) is a biotechnology company focused on developing regenerative medicine therapies, particularly using cellular and molecular approaches to address aging-related diseases and chronic conditions. The company emphasizes treatments derived from proprietary mesenchymal stem cell technology and other biologics to promote tissue repair and restore health.
Company News
Longeveron Inc. completed a public offering of 5,882,354 Class A common stock and short-term warrants, raising approximately $5 million, with potential additional proceeds of $12.5 million from warrant exercises. The company plans to use funds for clinical development of laromestrocel targeting various medical conditions.
Longeveron presented positive long-term survival data for its Lomecel-B treatment in patients with Hypoplastic Left Heart Syndrome (HLHS). The data showed 100% 5-year survival and transplant-free rates, outperforming historical data. The findings support the potential of Lomecel-B as an adjunct therapy to improve outcomes for HLHS patients.
Why New Investors Should Look Into Investing in Penny Stocks Penny stocks… The post Should New Investors Buy Penny Stocks? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Treatment derived from bone marrow shows promise in patients with mild Alzheimer's disease.